LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02 2024 - 5:50PM
Business Wire
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today
announced that a majority of the independent members of LENSAR’s
board of directors granted three newly-hired non-executive
employees stock options to purchase an aggregate of 1,200 shares of
the Company’s common stock. The options were granted as of July 2,
2024, as inducements material to each employee entering into
employment with the Company. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $4.31 per share, which is
equal to the closing price of the Company’s common stock on the
grant date. The options vest as to 25% of the total amount of the
award on the one-year anniversary of the vesting commencement date
of July 1, 2024 and in thirty-six substantially equal monthly
installments thereafter, subject to the new employee’s continued
service with the company. Each stock option has a 10-year term. The
options are subject to the terms and conditions of LENSAR’s 2024
Employment Inducement Incentive Award Plan and a stock option
agreement covering the grant.
About LENSAR
LENSAR is a commercial-stage medical device company focused on
designing, developing, and marketing advanced systems for the
treatment of cataracts and the management of astigmatism as an
integral aspect of the cataract procedure. LENSAR has developed its
next-generation ALLY® Adaptive Cataract Treatment System, the first
platform to integrate proprietary imaging and software, with an
extremely fast dual-pulse femtosecond laser in a compact, highly
ergonomic system. ALLY is designed to transform premium cataract
surgery by utilizing LENSAR’s advanced technologies with the
ability to perform the entire procedure in an operating room or
in-office surgical suite, delivering operational efficiencies and
reduced overhead. ALLY includes LENSAR’s proprietary Streamline®
software technology, designed to guide surgeons to achieve better
outcomes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701737677/en/
Contacts: Thomas R. Staab, II, CFO
ir.contact@lensar.com
Lee Roth / Cameron Radinovic Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com
LENSAR (NASDAQ:LNSR)
Historical Stock Chart
From Dec 2024 to Jan 2025
LENSAR (NASDAQ:LNSR)
Historical Stock Chart
From Jan 2024 to Jan 2025